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ABSTRACT
Introduction: Inflammatory bowel disease (IBD) is a
chronic intestinal disorder, often leading to an impaired
quality of life in affected patients. The importance of
environmental factors in the pathogenesis of IBD,
including their disease-modifying potential, is
increasingly recognised. Hypoxia seems to be an
important driver of inflammation, as has been reported
by our group and others. The aim of the study is to
evaluate if hypoxia can alter disease activity of IBD
measured by Harvey-Bradshaw Activity Index in
Crohn’s disease (increase to ≥5 points) and the partial
Mayo Score for ulcerative colitis (increase to ≥2
points). To test the effects of hypoxia under
standardised conditions, we designed a prospective
and controlled investigation in healthy controls and
patients with IBD in stable remission.
Methods and analysis: This is a prospective,
controlled and observational study. Participants
undergo a 3-hour exposure to hypoxic conditions
simulating an altitude of 4000 metres above sea level
(m.a.s.l.) in a hypobaric pressure chamber. Clinical
parameters, as well as blood and stool samples and
biopsies from the sigmoid colon are collected at
subsequent time points.
Ethics and dissemination: The study protocol was
approved by the Ethics Committee of the Kanton
Zurich (reference KEK-ZH-number 2013-0284). The
results will be published in a peer-reviewed journal and
shared with the worldwide medical community.
Trials registration number: NCT02849821;
Pre-results.
INTRODUCTION
Inﬂammatory bowel disease (IBD) is a
chronic intestinal disorder, often leading to
an impaired quality of life in affected patients.
The aetiology of IBD is not fully understood,
but the importance of environmental factors
in the pathogenesis of this disease, including
their disease-modifying potential, is increas-
ingly recognised. As such, hypoxia seems to
be an important driver of inﬂammation.1 2 In
healthy volunteers spending 3–4 days at an
elevation of 3400 metres above sea level (m.a.
s.l.), plasma levels of several inﬂammatory
Strengths and limitations of this study
▪ The prospective nature and the standardised
study conditions are a clear strength of our
study.
▪ A clinical study regarding the influence of
hypoxia has never been performed on patients
with inflammatory bowel disease before and we
have a well-characterised data collection, includ-
ing information on clinical status, and results on
blood and sigmoidoscopy.
▪ A limitation is that psychological stress in the
hypobaric chamber may lead to a release of
pro-inflammatory cytokines that could influence
inflammatory cascades.
▪ Another limitation is that a 3-hour exposure in
the hypobaric chamber might be too short to
show significant effects; however, if our analysis
shows significant regulatory effects on inflamma-
tory reactions, these would be even more
marked at a longer exposure.
▪ A further limitation is that the sample size calcu-
lation is not based on the primary outcome of
the study.
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markers, such as interleukin (IL)-6, IL-1 receptor antag-
onist and C reactive protein, were found to be increased.3
Moreover, we recently reported on the association of IBD
ﬂare-ups and antecedent journeys to high-altitude
regions and aircraft travels. Patients with IBD with at least
one ﬂare-up during a 12-month observation period were
compared with a group of patients in remission. Patients
with IBD experiencing ﬂare-ups had more frequently
undertaken ﬂights and/or journeys to regions >2000 m.a.
s.l. within 4 weeks of the ﬂare-up when compared with
patients in remission (21/52 (40.4%) vs 8/51 (15.7%),
p=0.005).4
The role of hypoxia as an inductor of inﬂammation has
also been studied extensively in vitro and in animal experi-
ments. Several studies showed that in vitro and in vivo
hypoxic conditions had an inﬂuence on the vascular barrier
function, posthypoxic endothelial permeability and neutro-
phil tissue accumulation.5–8 In addition, Rosenberger et al9
analysed the role of hypoxia-inducible factor (HIF)-1 and
hypoxia in inﬂammatory processes. They could show that
HIF-1-dependent induction of netrin-1 attenuates hypoxia-
elicited inﬂammation at mucosal surfaces.
Of note, hypoxia has been reported to be a disease-
modifying factor and pro-inﬂammatory stimulus in
several diseases, such as IBD, rheumatoid arthritis and
cancer.10–15 In addition, the impact of hypoxia on intes-
tinal transport proteins, exercise capacity, sleep, nutri-
tion, lung function, lipid metabolism and gastric
emptying in healthy mountaineers has been investigated.
It could be shown that, for example, reduced energy
intake after rapid ascent to high altitudes was associated
with severity of acute mountain sickness, but the under-
lying mechanisms are still unclear. Furthermore, intes-
tinal transport was affected during systemic exposure
to hypoxia in humans.16–18 Moreover, also iron uptake
is controlled in an oxygen-dependent manner.19
Gastrointestinal problems are a well-known complication
after high-altitude journeys. Anand et al20 as well as Wu
et al21 showed that the exposure to high altitude may lead
to gastroduodenal erosions and ulcer formation with con-
secutive gastrointestinal bleeding. In an own study, we
investigated healthy volunteer mountaineers before and
after an ascent to 4500 m.a.s.l. The participants under-
went an endoscopy before the ascent and two further
endoscopies at day 2 and day 4 after the ascent at 4500 m.
a.s.l. In the ﬁrst baseline endoscopy, only one participant
showed reﬂux oesophagitis, all other participants had a
normal oesophagogastroduodenoscopy. At day 2 at
4500 m.a.s.l., 28% (4 out of 23) of the mountaineers
showed pathological ﬁndings, including duodenal ero-
sions/ulcers and haemorrhagic gastritis/duodenitis. At
day 4, 61% (16 out of 23) of the participants showed
endoscopic abnormalities. These results underline that
exposure to hypoxic conditions may have profound
effects on the gastrointestinal tract.22
To evaluate the potential inﬂuence of hypoxia on the
course of IBD on a cellular level and to analyse the
effects of hypoxia under standardised conditions, we
designed a prospective and controlled investigation in
patients with IBD in stable remission and compared them
with healthy volunteers. Our primary aim is to show that
a 3-hour stay at high altitude might alter disease activity
of IBD. A total of 10 healthy volunteers, 11 patients with
Crohn’s disease (CD) and 9 patients with ulcerative
colitis (UC) undergo a 3-hour exposure to hypoxic condi-
tions simulating an altitude of 4000 m.a.s.l. (13 000 ft
Flight Level (FL)) in a hypobaric low-pressure chamber
situated at the Swiss Aeromedical Center, Dubendorf,
Switzerland. The hypobaric pressure chamber is set to
pressure of 462 mm Hg to simulate the conditions at
4000 m.a.s.l., the PaO2 is 7 kPa. Of note, the cabin pres-
sure in a standard aeroplane correlates with 2000 to
2500 m.a.s.l., at 2000 m.a.s.l. the PaO2 is 10 kPa. Stool
samples for the analysis of calprotectin and microbiota
composition, biopsy samples from the rectosigmoid
region and blood samples are repetitively collected and
analysed in conjunction with detailed records of clinical
symptoms over a subsequent interval of 4 weeks.
METHODS AND ANALYSIS
Study design
The study was designed as a prospective, controlled and
observational study.
Inclusion and exclusion criteria
Patients are eligible if they
▸ Are ≥18 and <60 years of age;
▸ Have a diagnosis of CD or UC at least 6 months prior
to inclusion;
▸ Give written consent;
▸ Are in clinical remission (measured by Harvey-
Bradshaw Activity Index (HBI) in CD and the partial
Mayo Score for UC).
Patients were not eligible if they
▸ Have contraindications for a sigmoidoscopy;
▸ Have intercurrent bacterial or viral intestinal disease
(by culture or serology);
▸ Are pregnant or breast feeding;
▸ Have a severe concomitant disease which excluded
them from participating in the study by means of the
study physician;
▸ Are likely to or showed no cooperation for the study
procedures;
▸ Have active infection or systemic antibiotic, antiviral
or antifungal treatment 3 weeks before baseline;
▸ Are suffering from short-bowel syndrome;
▸ Are receiving parenteral nutrition;
▸ Have a clinical condition which did not allow a stay at
heights of 4000 m.a.s.l.;
▸ Are claustrophobic.
Primary and secondary outcomes
Primary outcome
A 3-hour stay at high altitude (4000 m, 13 000 ft Flight
Level (FL)) can alter disease activity of IBD measured by
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HBI in CD (increase to ≥5 points) and the partial Mayo
Score for UC (increase to ≥2 points).
Secondary outcomes
▸ Change of the volume state of the body due to
hypoxia (repetitive measurements of bladder volume;
measurement of angiotensin and vasopressin in urine
and measurement of renin, aldosterone, vasopressin
and angiotensin in blood).
▸ Show that a 3-hour stay at high altitude (4000 m,
13 000 ft Flight Level (FL)) modulates biochemical
pro-inﬂammatory response pathways in patients with
IBD and healthy individuals, and investigate whether
this response differs between the two groups.
Procedure of the study
In brief, patients undergo a 3-hour exposure to hypoxic
conditions simulating an altitude of 4000 m.a.s.l. in a
hypobaric low-pressure chamber situated at the Swiss
Aeromedical Center, Dubendorf, Switzerland (ﬁgures 1
and 2). The pressure in the hypobaric low-pressure
chamber was 462 mm Hg and PaO2 was 7 kPa. Stool
samples to analyse calprotectin and microbial compos-
ition, biopsy samples from the rectosigmoid region and
blood samples are repetitively collected and analysed
over a period of 4 weeks in conjunction with detailed
records of clinical symptoms. In detail, the study is divided into screening (S), base-
line (T0), visit 1 (T1), visit 2 (T2) and visit 3 (T3)
(ﬁgure 3):
Screening
During the screening procedure, the inclusion and
exclusion criteria are assessed, and the patients give
written consent. The patients receive a clinical examin-
ation including an otolaryngological examination, as
well as vital signs (heart rate and blood pressure) and
body temperature assessment. Demographic data, per-
sonal medical history, medication and anamnesis are
also assessed.
Baseline (T0)
Baseline (T0) takes place 1 day before the stay in the
hypobaric chamber. At T0, inclusion and exclusion cri-
teria are reassessed, patients receive a clinical examin-
ation; vital signs (heart rate and blood pressure), body
temperature, medication, adverse events and HBI
(patients with CD) or partial Mayo Score (patients with
UC) are assessed. Blood is drawn and a stool sample is
obtained. Patients undergo a sigmoidoscopy and six
biopsies from the sigmoid region are taken.
Visit 1 (T1)
Visit 1 (T1) is performed 1 day after baseline. At T1, the
patients receive a clinical examination, including an oto-
laryngological examination, and vital signs (heart rate
and blood pressure), body temperature, medication,
adverse events and HBI (patients with CD) or partial
Mayo Score (patients with ulcerative colitis) are assessed.
Figure 1 Hypobaric low-pressure chamber at the Swiss
Aeromedical Center, Dubendorf, Switzerland.
Figure 2 Control room of the hypobaric low-pressure
chamber at the Swiss Aeromedical Center, Dubendorf,
Switzerland.
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Blood is drawn directly before the stay in the hypobaric
chamber. Patients then enter the hypobaric chamber
(ascent within 10 min, 3-hour exposure to hypoxic con-
ditions simulating an altitude of 4000 m.a.s.l. (FL 13 000
ft,) afterwards controlled descent under continuous pul-
soximetric control). During the 3-hour stay in the hypo-
baric chamber, repetitive measurements of the bladder
volume are performed (5 min after reaching the altitude
of 4000 m.a.s.l., and at time points 30, 45, 60, 120,
180 min and after the descent) by ultrasonography.
Directly after the stay in the hypobaric chamber, blood is
drawn again. A sigmoidoscopy from the sigmoid region
is performed (at the latest 2 hours after leaving the
hypobaric chamber) and six biopsies, remote of previous
biopsy areas, are collected.
Visit 2 (T2)
Visit 2 (T2) takes place 7 days after the stay in the hypo-
baric chamber. At T2, patients receive a clinical examin-
ation, and vital signs (heart rate and blood pressure),
body temperature, medication, adverse events and HBI
(patients with CD) or partial Mayo Score (patients with
UC) are assessed. Blood is drawn and a stool sample is
obtained, prior to a sigmoidoscopy where six biopsies
from the sigmoid region, remote of previous biopsy
areas, are taken.
Visit 3 (T3)
Visit 3 (T3) takes place 30 days after the stay in the hypo-
baric chamber. At T3, the patients receive a clinical
examination, and vital signs (heart rate and blood pres-
sure), body temperature, medication, adverse events and
HBI (patients with CD) or partial Mayo Score (patients
with UC) are assessed. Blood is also drawn and a stool
sample is obtained.
Study procedures
Sigmoidoscopy with biopsies from the sigmoid region
To retrieve biopsies from the colon during the course of
the study, three sigmoidoscopies are performed. For
endoscopy, Olympus EVIS EXERA III (GIF-H190) and
Olympus EVIS EXERA (CF-Q160) are used. The ﬁrst
sigmoidoscopy is performed 1 day before the stay in the
hypobaric chamber. The second sigmoidoscopy is per-
formed directly after the hypobaric chamber and the
third sigmoidoscopy is performed 1 week after the hypo-
baric chamber. During each sigmoidoscopy, six biopsies
are taken with standard size forceps (2.4 mm). One
biopsy is analysed by real-time quantitative PCR for HIF-1,
as well as pro-inﬂammatory and anti-inﬂammatory cyto-
kines (eg, interferon-γ, IL-8, tumour necrosis factor,
IL-1β, IL-6, IL-10 and transforming growth factor-β),
pattern recognition receptors (eg, toll-like receptor 4 and
nucleotide-binding oligomerisation domain-containing
protein (NOD) 2), inﬂammasome-associated proteins
(NOD-like receptor family pyrin domain containing
(NLRP) 3, IL-1β, IL-18 and caspase 1), autophagy factors
(eg, microtubule-associated proteins 1A/1B, light chain
3B (MAPLC3B) and sequestosome-1) and tissue remod-
elling factors (eg, matrix metalloproteinase 9 and smooth
muscle α-actin). One biopsy is analysed by western blot
for HIF-1, nuclear factor (NF)-κB signalling pathway acti-
vation (eg, phospho-NF-κB and phospho-inhibitor of κB,
autophagy factors (sequestosome-1, MAPLC3B and mam-
malian target of rapamycin) and inﬂammasome-
associated factors (eg, NLRP3). Another biopsy is
analysed for gene expression by in situ hybridisation for
pro-inﬂammatory and anti-inﬂammatory factors. Two
biopsies are analysed by immunohistochemistry for
phospho-NF-κB and one biopsy is stained with H&E.
Faecal calprotectin
Faecal calprotectin levels are measured at the University
Hospital Zurich by a novel ELISA-based calprotectin test
(EliA calprotectin, Thermo Scientiﬁc).23
Measurement of the volume state
The volume state was measured to evaluate possible
high-altitude diuresis24 and to determine corresponding
changes of volume-regulatory hormones.
Measurement of bladder volume
During the 3-hour stay in the hypobaric chamber, repeti-
tive measurements of the bladder volume are performed
Figure 3 Study design.
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(5 min after reaching the altitude of 4000 m.a.s.l., and at
time points 30, 45, 60, 120, 180 min and after the
descent). The volume of the bladder is assessed by
ultrasonography.
Variables in blood and urine
Urine samples for the measurement of angiotensin and
vasopressin are obtained before and after the hypobaric
chamber. EDTA-blood is drawn before and after the
hypobaric chamber for the measurement of renin,
aldosterone, vasopressin and angiotensin.
Sympathicotonic reaction
Blood pressure and pulse are measured before and after
the hypobaric chamber, as well as every 15 min during
the stay in the hypobaric chamber. Furthermore, cate-
cholamines (epinephrine and norepinephrine) are mea-
sured before and after the stay in the hypobaric
chamber.
ANGII (Sigma-Aldrich, St. Louis, Missouri, USA) and
aldosterone (R&D Systems, Minneapolis, Minnesota,
USA) concentrations are quantiﬁed by means of a
competitive enzyme immunoassay and renin activity
by a ﬂuorometric assay kit (BioVision, Milpiates,
California, USA).
Assessment of safety
Continuous pulsoximetric monitoring during the stay in
the hypobaric chamber is performed. The minimum
oxygen saturation, measured by pulsoximetric monitor-
ing, that is accepted during stay in the hypobaric
chamber is 70%.
Calculation of clinical activity
To calculate the clinical activity of patients with CD, the
HBI is used.25 This index includes general well-being,
abdominal pain, the number of bowel movements,
abdominal resistance and CD-associated extraintestinal
diseases. Each category has a point value assigned and
from the sum of all categories a point value is
calculated.
Patients with an overall value of <5 points are in clin-
ical remission, patients with 5–7 points have mild, with
8–16 points moderate and with >16 points severe
disease.
To calculate the clinical activity of patients with UC,
the partial Mayo Score is used.26 This clinical index
includes the stool frequency, the amount of blood in the
stool and the physician rating of disease activity. Each
category has a point value assigned from 0 to 3 and
from the sum of all categories a point value was calcu-
lated. Remission is deﬁned as 0–1 points, mild disease
2–4 points, moderate disease 5–6 points and severe
disease as 7–9 points.
Administration of patient records
All documents containing patient data carry the respect-
ive patient code assigned by the physician. Encoded
documents are stored at the Department of
Gastroenterology and Hepatology, University of Zurich,
Switzerland, and will be stored for 10 years. Only the
study team has access to the patient codes. Data entry is
performed continuously at the Department of
Gastroenterology and Hepatology, and if data are
missing, a research assistant investigates to obtain all
information as required.
Sample size calculation
In a pilot study with healthy controls (Wojtal et al,
unpublished), the ideal apical sodium-dependent bile
acid transporter (ASBT) had a mean reduction of 49%
compared with baseline measurements (SD 15%). The
power to detect a reduction of 67% among patients with
IBD is then 80% with n=14 patients and n=14 controls.
The calculation is based on a two-sided t-test of the log
ASBT measurements with signiﬁcance level of 5%.
About the same power is reached if n=20 patients are
compared with n=10 controls.
Statistical data evaluation
The statistical data evaluation will be performed by the
Institute of Epidemiology, Biostatistics and Prevention at
the University of Zurich, Switzerland. Statistical analysis
of the clinical data will be performed using a paired
Student’s t-test, and probabilities (p, two tailed) of
p<0.05 are considered statistically signiﬁcant. For statis-
tical analysis of groups, one-way analysis of variance
(ANOVA) will be performed followed by the Tukey’s
Post Hoc test. Differences are considered signiﬁcant at
p<0.05, highly signiﬁcant at p<0.01 and very highly sig-
niﬁcant at p<0.001.
Patient recruitment
Twenty patients with IBD and 10 healthy controls are
included in the study. The patients are recruited from
the IBD clinic of the Division of Gastroenterology
and Hepatology of the University Hospital Zurich.
The healthy controls are recruited age-matched and sex-
matched from colleagues of the study team.
Patient informed consent
Prior to study participation, patients receive written and
oral information about the content and extent of the
planned study. In case of acceptance, they sign the
informed consent form. In case of study discontinuation,
all material will be destroyed or the patient will be asked
if he/she accepts that the existing material can be used
for the study.
Time frame of the study
Recruitment of patients and healthy volunteers was
started in May 2014. The ﬁrst group of ﬁve healthy
volunteers was included into the study on December
2014. The ﬁrst ﬁve patients with IBD were included in
March 2015, last data collection is ongoing and is
planned to be completed until 31 December 2016.
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DISSEMINATION
The results will be published in a peer-reviewed journal
and shared with the worldwide medical community.
DISCUSSION
The importance of environmental factors in the patho-
genesis of IBD, including their disease-modifying poten-
tial, is increasingly recognised. One factor that has come
to the fore is hypoxia, which seems to play an important
role in inﬂammatory processes.3 Numerous investiga-
tions in animal models and humans suggest that
hypoxia has a profound inﬂuence on the integrity
and function of the gastrointestinal tract, epithelial
barrier, immune system and microbial composition.
Furthermore, an increasing body of evidence points to
that exposure to hypoxia (as in airline travel and high-
altitude journeys) could be associated with various
gastrointestinal symptoms and may have an impact on
the pathogenesis and course of disease in IBD.
Furthermore, in murine models of IBD intracellular
hydroxylases, a group of enzymes responsible for oxygen
sensing and activation of adaptive transcriptional
responses to hypoxia, were identiﬁed as a new class of
therapeutic targets in IBD.27–29 However, the integrative
mechanisms underlying the role of hypoxia in inﬂam-
mation, and especially in the pathogenesis of IBD, are
still not well deﬁned.
Up to date, standardised conditions to evaluate the
effects of hypoxia in IBD are lacking. Evaluating subjects
at high altitudes, as it was done by our group with volun-
tary mountaineers, is complex, and is also mainly
limited to healthy and athletic subjects, that are able to
conduct such a journey.22 Furthermore, at high altitudes
facilities to timely process blood and tissue are lacking
and conditions for interventional diagnostics, like endos-
copies, are limited. Therefore, we developed an environ-
ment where patients and healthy volunteers could be
exposed to hypoxic conditions simulating an altitude of
4000 m.a.s.l. With this setup, we are able to perform pro-
spective and controlled investigations under standar-
dised conditions and still have access to the facilities of
our University Hospital. Understanding clinical, molecu-
lar and microbiological consequences of intestinal
hypoxia may ultimately derive further insights on the
pathogenesis of IBD, far beyond exposure to lower
partial oxygen pressure ambient air.
Trial status
The study procedures started in September 2015. Data
collection was started in January 2016 and is ongoing.
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